JP2015505309A5 - - Google Patents

Download PDF

Info

Publication number
JP2015505309A5
JP2015505309A5 JP2014549542A JP2014549542A JP2015505309A5 JP 2015505309 A5 JP2015505309 A5 JP 2015505309A5 JP 2014549542 A JP2014549542 A JP 2014549542A JP 2014549542 A JP2014549542 A JP 2014549542A JP 2015505309 A5 JP2015505309 A5 JP 2015505309A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
sequence identity
acid sequence
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014549542A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015505309A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2011/056006 external-priority patent/WO2013098589A1/en
Publication of JP2015505309A publication Critical patent/JP2015505309A/ja
Publication of JP2015505309A5 publication Critical patent/JP2015505309A5/ja
Pending legal-status Critical Current

Links

JP2014549542A 2011-12-29 2011-12-29 髄膜炎菌h因子結合タンパク質のアジュバントされた組み合わせ Pending JP2015505309A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2011/056006 WO2013098589A1 (en) 2011-12-29 2011-12-29 Adjuvanted combinations of meningococcal factor h binding proteins

Publications (2)

Publication Number Publication Date
JP2015505309A JP2015505309A (ja) 2015-02-19
JP2015505309A5 true JP2015505309A5 (enExample) 2015-04-02

Family

ID=45529152

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014549542A Pending JP2015505309A (ja) 2011-12-29 2011-12-29 髄膜炎菌h因子結合タンパク質のアジュバントされた組み合わせ

Country Status (7)

Country Link
US (1) US10596246B2 (enExample)
EP (1) EP2797624A1 (enExample)
JP (1) JP2015505309A (enExample)
AU (1) AU2011384634A1 (enExample)
BR (1) BR112014016223A8 (enExample)
CA (1) CA2862247A1 (enExample)
WO (1) WO2013098589A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2857499A1 (en) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
BR112017025954A2 (pt) * 2015-06-02 2018-08-14 De Staat Der Nederlanden, Vert. Door De Minister Van Vws, Ministerie Van Volksgezondheid, Welzijn En Sport apresentação em superfície de antígenos em vesículas de membrana externa gram-negativa
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4663160A (en) 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4761283A (en) 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US5204098A (en) 1988-02-16 1993-04-20 The United States Of America As Represented By The Department Of Health And Human Services Polysaccharide-protein conjugates
NL8802046A (nl) 1988-08-18 1990-03-16 Gen Electric Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen.
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
AU651949B2 (en) 1989-07-14 1994-08-11 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
ATE128628T1 (de) 1990-08-13 1995-10-15 American Cyanamid Co Faser-hemagglutinin von bordetella pertussis als träger für konjugierten impfstoff.
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
US5425946A (en) 1992-08-31 1995-06-20 North American Vaccine, Inc. Vaccines against group C Neisseria meningitidis
CA2142981C (en) 1992-08-31 2007-10-23 Joseph Y. Tai Vaccines against group c neisseria meningitidis
NL9201716A (nl) 1992-10-02 1994-05-02 Nederlanden Staat Buitenmembraanvesikel dat voorzien is van een groep polypeptiden welke ten minste de immuunwerking van aan membraan gebonden buitenmembraaneiwitten (OMP's) hebben, werkwijze ter bereiding ervan alsmede een vaccin dat een dergelijk buitenmembraanvesikel omvat.
US5698438A (en) 1994-10-18 1997-12-16 Oregon Health Sciences University Bacterial hemoglobin receptor gene
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
AU7701098A (en) 1997-05-28 1998-12-30 Michael A. Apicella Laft mutants of pathogenic gram-negative bacteria
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
US6645503B1 (en) 1998-03-10 2003-11-11 Wyeth Holdings Corporation Antigenic conjugates of conserved lipopolysaccharides of gram negative bacteria
MX343752B (es) 1998-05-01 2016-11-22 Novartis Vaccines & Diagnostics Inc Antigenos de neisseria meningitidis y composiciones que los contienen.
CN1263510C (zh) 1998-08-19 2006-07-12 巴克斯特健康护理股份有限公司 多糖-蛋白质缀合物或寡糖-蛋白质缀合物、其制备方法及其应用
CA2347849C (en) 1998-10-22 2013-06-25 The University Of Montana Omp85 proteins of neisseria gonorrhoeae and neisseria meningitidis, compositions containing same and methods of use thereof
PT1127137E (pt) 1998-11-03 2007-12-28 Staat Nl Verteg Door Min Welzi Lps com toxicidade reduzida a partir de bactérias gramnegativas modificadas geneticamente
WO2000033882A1 (en) 1998-12-04 2000-06-15 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services A vi-repa conjugate vaccine for immunization against salmonella typhi
CA2366152A1 (en) 1999-03-19 2000-09-28 Smithkline Beecham Biologicals S.A. Streptococcus pneumoniae vaccine
WO2000061761A2 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
NZ571167A (en) 1999-04-30 2010-05-28 Novartis Vaccines & Diagnostic Fragments from Neisseria protein ORF 953 and their use in medicaments and diagnostic reagents
US6531131B1 (en) 1999-08-10 2003-03-11 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for Neisseria meningitidis
GB9923176D0 (en) 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
ATE460484T1 (de) 1999-11-29 2010-03-15 Novartis Vaccines & Diagnostic 85 kda antigen von neisseria
AU2818101A (en) 2000-01-25 2001-08-07 University Of Queensland, The proteins comprising conserved regions of neisseria meningitidis surface antigen NhhA
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
AU2002309706A1 (en) 2001-05-11 2002-11-25 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
DE60325696D1 (de) 2002-02-22 2009-02-26 Ca Nat Research Council Synthese von lipopolysaccharid-protein konjugatvaccinen über die lipid-a region nach entfernung des glycosidischen phosphatresidüs
ES2616180T3 (es) 2002-03-26 2017-06-09 Glaxosmithkline Biologicals Sa Sacáridos modificados con estabilidad mejorada en agua para su uso como medicamento
CN1674933B (zh) 2002-08-02 2012-09-26 葛兰素史密丝克莱恩生物有限公司 疫苗组合物
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
BRPI0409459A (pt) 2003-04-16 2006-05-02 Wyeth Corp novas composições imunogênicas para a prevenção e tratamento de doença meningocócica
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
GB0419408D0 (en) 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
PL1866342T3 (pl) 2005-04-08 2019-04-30 Wyeth Llc Oddzielanie zanieczyszczeń od polisacharydu Streptococcus pneumoniae przez manipulację pH
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
IL308456A (en) 2005-04-08 2024-01-01 Wyeth Llc A multivalent pneumomuroral protein-polysaccharide conjugate preparation
HUE045482T2 (hu) 2005-06-27 2019-12-30 Glaxosmithkline Biologicals Sa Immunogén készítmény
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
JP5792920B2 (ja) 2005-12-22 2015-10-14 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
ES2337309T5 (es) 2006-06-12 2013-07-30 Glaxosmithkline Biologicals S.A. Vacuna
CA2665169C (en) 2006-10-10 2017-02-21 Wyeth Purification of streptococcus pneumoniae type 3 polysaccharides
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
WO2009038889A1 (en) 2007-08-02 2009-03-26 Children's Hospital And Research Center At Oakland Fhbp- and lpxl1-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
AU2009215364B2 (en) 2008-02-21 2014-09-18 Glaxosmithkline Biologicals S.A. Meningococcal fHBP polypeptides
CN104548082A (zh) 2009-03-24 2015-04-29 诺华股份有限公司 为脑膜炎球菌因子h结合蛋白添加佐剂
WO2011161653A1 (en) 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
CA2808975C (en) 2010-08-23 2018-10-30 Wyeth Llc Stable formulations of neisseria meningitidis rlp2086 antigens
KR101584871B1 (ko) * 2010-09-10 2016-01-22 와이어쓰 엘엘씨 네이세리아 메닝기티디스 orf2086 항원의 비-지질화된 변이체

Similar Documents

Publication Publication Date Title
RU2375374C2 (ru) Домены и эпитопы менингококкового белка nmb1870
JP2014503172A5 (enExample)
JP2013502918A5 (enExample)
JP2013520487A5 (enExample)
RU2012149618A (ru) Менингококковые полипептиды fhbp
CN104844712B (zh) 肺炎链球菌蛋白抗原及其制备方法和应用
RU2007139915A (ru) Haemophilus influenzae типа в
BRPI0721003B8 (pt) composições e uso
RU2005119640A (ru) Множественные варианты менингококкового белка nmbi1870
CN102711794A (zh) 用于疫苗和诊断学的Dps融合蛋白
JP2016040284A5 (enExample)
JP2014507146A5 (enExample)
JP2015500827A5 (enExample)
JP2010508276A5 (enExample)
JP2012516140A5 (enExample)
JP2013504556A5 (enExample)
JP2012521404A5 (enExample)
JP2011517938A5 (enExample)
JP2012524099A5 (enExample)
JP2014502961A5 (enExample)
US11732031B2 (en) Method for producing influenza HA split vaccine
Leng et al. Recombinant bacterial lipoproteins as vaccine candidates
RU2015106916A (ru) Полипептиды clostridium difficile в виде вакцины
JP5661744B2 (ja) 腸球菌由来のポリペプチド、及びワクチン接種のためのその使用
JP2018537107A5 (enExample)